百济神州穿越“死亡谷”：首次实现全年盈利 下一波增长点在哪？

Core Viewpoint - BeiGene has reported a significant increase in revenue and net profit for the fiscal year 2025, indicating a successful transition from a loss-making entity to a profitable one, driven by strong product sales and effective cost management [1][3]. Financial Performance - Total revenue for 2025 reached RMB 38.205 billion, a year-on-year increase of 40.4% [1]. - Net profit attributable to the parent company was RMB 1.422 billion [1]. - Product revenue amounted to RMB 37.770 billion, reflecting a growth of 39.9% [1]. Product Performance - The sales of the leading product, Brukinsa® (Zebutinib), reached RMB 28.067 billion, marking a 48.8% increase [1]. - In the U.S., Brukinsa® sales were RMB 20.206 billion, up 45.5% [1]. - In Europe, sales were RMB 4.265 billion, a growth of 66.4% [1]. - In China, sales reached RMB 2.472 billion, increasing by 33.1% [1]. Market Expansion and Clinical Trials - Brukinsa® is now approved in over 75 markets globally, establishing itself as the most widely approved BTK inhibitor [2]. - Upcoming clinical trials include a mid-term analysis of the MANGROVE trial for Brukinsa® in combination with Rituximab for adult patients with mantle cell lymphoma [2]. - The sales of another key product, Tislelizumab (百泽安®), reached RMB 5.297 billion, an 18.6% increase [2]. Future Projections - Revenue for 2026 is projected to be between RMB 43.6 billion and RMB 45 billion, with a gross margin expected to remain high at around 80% [4]. - Research and development expenses are anticipated to be between RMB 33.3 billion and RMB 34.8 billion [4]. Pipeline and Innovation - The company is advancing several late-stage products in the hematologic oncology field, including the BCL2 inhibitor, which has received approval for its first global marketing application in China [4]. - The introduction of BTK inhibitors and IRAK4 degraders into autoimmune diseases represents a strategic expansion into non-oncology markets [5]. Market Position and Valuation - Despite achieving profitability, the company's market valuation remains high, with a significant price-to-earnings ratio, indicating that the market views it as a growth stock rather than a value stock [5].